| After Rival Stumbles, Relypsa Gets $1.5B Buyout Bid From Galenica | Ben Fidler | 07/21/16 | San Francisco |
| Syndax Cuts Price But Bags $53M in Second IPO Try | Ben Fidler | 03/02/16 | Boston |
| As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO | Ben Fidler | 11/14/14 | San Francisco |
| West Coast Biotech Roundup: Affymax, K2, Roche/Stratos, & More | Alex Lash | 06/26/14 | San Francisco |
| Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal | Luke Timmerman | 03/18/13 | San Francisco |
| Has The Pendulum Swung Too Far in Favor of Rare Diseases? | Stewart Lyman | 03/14/13 | Seattle |
| Some Bold Baseball and Biotech Picks for the 2013 Season | Luke Timmerman | 03/11/13 | National |
| Affymax, Takeda Win Approval of Anemia Drug to Challenge Amgen | Luke Timmerman | 03/27/12 | San Francisco |
| Some Tongue-in-Cheek Fantasy Baseball (and Biotech) Picks | Luke Timmerman | 03/26/12 | National |
| Affymax Prepares to Mount Challenge to Amgen Anemia Drug Monopoly | Luke Timmerman | 01/25/12 | San Francisco |
| Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug | Luke Timmerman | 12/07/11 | San Francisco |
| Affymax Shares Climb As FDA Considers Wider Use for Anemia Drug | Luke Timmerman | 12/05/11 | San Francisco |
| Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny | Luke Timmerman | 11/17/11 | San Francisco |
| FDA Says It Will Review Affymax Drug | Luke Timmerman | 07/27/11 | San Francisco |
| SV Feels Lonely at the Top, Canaan Finds Biotech Groove, Portola Gets Drug Back, & More in Bay Area Life Sciences News | Luke Timmerman | 03/25/11 | San Francisco |
| Affymax Raises $50M | Luke Timmerman | 03/18/11 | San Francisco |
| E-Commerce Pioneer Sets Up Cancer Commons, Affymax Hires New Boss, Plexxikon Opts In, & More Bay Area Life Sciences News | Luke Timmerman | 01/07/11 | San Francisco |
| Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug | Luke Timmerman | 01/06/11 | San Francisco |
| Codexis Morphs From Big Science Project Into $100M Business | Luke Timmerman | 10/27/10 | San Francisco |
| Edmund Shea Jr. Dies at 80 | Wade Roush | 08/16/10 | San Francisco |
| Affymax Isn’t Dead Yet, ZeaChem Pursues Wood Chip Ethanol, Third Rock Heads West, & More Bay Area Life Sciences News | Luke Timmerman | 08/13/10 | San Francisco |
| Nuon Adds $10M Debt, Options | Luke Timmerman | 08/12/10 | San Francisco |
| Affymax Lives to Fight Another Day, In Bid to Challenge Amgen’s Monopoly | Luke Timmerman | 08/09/10 | San Francisco |
| Genentech’s Souped-Up Antibody, Reg Kelly’s Mission, LS9 Nears Moment of Truth & More Bay Area Life Sciences News | Luke Timmerman | 06/25/10 | San Francisco |
| Affymax Tanks on Anemia Results | Luke Timmerman | 06/21/10 | San Francisco |
| San Diego’s Palkion Chases Amgen’s Big Market, Joins Race to Develop Oral Anemia Drug | Luke Timmerman | 09/01/09 | San Diego |
